Ardsley Advisory Partners LP Sells 75,000 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Ardsley Advisory Partners LP lessened its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 13.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 500,000 shares of the company's stock after selling 75,000 shares during the quarter. Ardsley Advisory Partners LP owned 0.10% of Elanco Animal Health worth $6,055,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health in the third quarter valued at approximately $35,000. Jones Financial Companies Lllp increased its holdings in Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. raised its position in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after purchasing an additional 3,411 shares during the last quarter. MRP Capital Investments LLC acquired a new position in Elanco Animal Health in the fourth quarter worth $61,000. Finally, Blue Trust Inc. grew its holdings in shares of Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after purchasing an additional 1,894 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Trading Down 1.2 %

Shares of ELAN stock traded down $0.12 during trading hours on Monday, reaching $9.63. The company had a trading volume of 4,374,028 shares, compared to its average volume of 4,946,557. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $18.80. The company has a 50 day moving average of $9.86 and a 200 day moving average of $11.45. The firm has a market cap of $4.78 billion, a price-to-earnings ratio of 24.08, a P/E/G ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the firm posted $0.08 earnings per share. Elanco Animal Health's quarterly revenue was down 1.4% compared to the same quarter last year. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the transaction, the director now owns 101,459 shares of the company's stock, valued at $1,105,903.10. This trade represents a 10.93 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.89% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on ELAN. UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus decreased their price target on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $14.67.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.